Company Overview and News

5
Derek Handley under fire at Sky Television AGM

2018-10-18 nzherald.co.nz
An otherwise limp Sky TV annual meeting was enlivened when a shareholder objected to board candidate Derek Handley.
MDPEB MDP

17
Wall Street Targets 90 Champions, Contenders, And Challengers As Dividend Stars For October

2018-10-03 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24, Challengers have 5-9. WallStar selections all show .05% or higher price target upsides.
ENBBF NYSE PEGI TLP HMLP NRZ ENB EPD MDP SEP SRLP ENB EQM VGR PBFX SIR APU MDPEB SUN PEG EBBNF

5
Bear Of The Day: Pilgrim's Pride Corp (PPC)

2018-09-24 zacks
Pilgrim's Pride Corporation (PPC - Free Report) is a Zacks Rank #5 (Strong Sell) after posting a recent miss of the Zacks Consensus Estimate. The estimates have slipped but it may still be worth a deeper look. As the Bear of the Day, we look at why this stock is a Zacks Rank #5 (Strong Sell).
MDPEB LB MDP PPC TITN

6
Bear of the Day: Campbell Soup Company (CPB)

2018-09-21 zacks
Campbell Soup Company (CPB - Free Report) shares have plummeted roughly 21% over the last three years as the packaged food firm tries to navigate shifting consumer habits and the proliferation of healthier upstart options.
MDPEB PF LB MDP

7
Dividend Champion Spotlight: Meredith Corporation

2018-09-21 seekingalpha
Meredith Corporation is a media conglomerate whose portfolio of national brands and local broadcasting stations has fueled 25 years of dividend raises with advertising revenues.
MDPEB MDP TIME

6
Bear of the Day: L Brands (LB)

2018-09-20 zacks
L Brands, Inc. (LB - Free Report) continues to struggle as its brands are off trend. This Zacks Rank #5 (Strong Sell) is near 5-year lows. L Brands operates 3,084 stores in the United States, Canada, the United Kingdom and Greater China. Its brands include Victoria's Secret, PINK, Bath & Body Works, La Senza and Henri Bendel. It also operates e-commerce sites for most of those brands and has 800 additional franchised locations worldwide.
MDPEB AEO M LB MDP

5
Meredith Corporation (MDP) Lags Q4 Earnings Estimates

2018-09-19 zacks
Meredith Corporation (MDP - Free Report) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.
UNP MDPEB MDP

6
Bear of the Day: MercadoLibre (MELI)

2018-09-19 zacks
The success of growth-minded investing over the past few years has made many people quick to overlook volatility and risk in favor of potential. This is all well and good, but there remains a number of red flags which should compel investors to stay away from even the most hopeful companies during periods of uncertainty. I think that’s exactly what we have in MercadoLibre (MELI - Free Report) right now.
MDPEB MELI MDP

8
Why Salesforce (CRM) Stock Is A Strong Buy Right Now

2018-09-18 zacks
Shares of Salesforce (CRM - Free Report) are up over 7% in the last month as the customer relationship management firm continues its impressive run. So, let's take some time to see why Salesforce stock appears to be a strong buy even as it sits near its new high.
MDPEB MSFT MDP VMW ORCL

6
Avon Stock Rallies on Takeover Talks With Brazil's Natura

2018-09-18 zacks
Shares of Avon Products, Inc. (AVP - Free Report) rallied 13.9% in after-hours trading on Sep 17. Per sources, the stock gained on rumors related to its potential takeover by Natura & Co — the leading Brazilian manufacturer and direct-seller of beauty and personal care products. However, Natura denies rumors of any such buyout talks with Avon. Earlier, the company had received “expressions of interest” from other parties.
CLXT TXN MDPEB AVP NUS MDP

6
QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

2018-09-18 zacks
Of late, QIAGEN N.V. (QGEN - Free Report) announced its new development under the company’s long-standing partnership with In Vitro Diagnostics (IVD) player DiaSorin. This time, the companies’ alliance is set to offer a fully-automated CE-Marked testing for latent tuberculosis (TB) infection with QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin LIAISON Platforms.
MASI TXN MDPEB AMED ISRG MDP

13
Kirkland's Loses 27% in 3 Months, High Costs a Major Hurdle

2018-09-18 zacks
Kirkland's, Inc.’s (KIRK - Free Report) shares have been on losing grounds, lately. Shares of this Zacks Rank #4 (Sell) company have plunged 27% in the past three months compared with the industry’s decline of 5.2%. Well, this retailer of home decor products has been biting the bullet due to comparable store sales (comps) decline, higher operating expenses and gross margin weakness. Higher Costs a Worry for Kirkland's Persistent weakness in gross margin is one of the major deterrents for Kirkland's performance.
KIRK TGT BURL TXN MDPEB URBN MDP

5
Markel's Premium Growth Encourages, Rising Costs a Drag

2018-09-18 zacks
Markel Corporation (MKL - Free Report) is expected to deliver premium growth in the upcoming quarters, driven by a superior performance by its Insurance and Reinsurance segments. Moreover, a strong performance at general liability and personal lines has been contributing to this property and casualty (P&C) insurer’s improving U.S. operations and we expect the momentum to continue in the near future.
TXN RNR MDPEB NAVG MDP Y MKL

6
Play Oracle's Q1 Earnings Beat With These 3 Tech Funds

2018-09-18 zacks
Oracle Corporation (ORCL - Free Report) posted favorable earnings results in its fiscal first quarter. Although the software company posted a marginal revenue miss, on the earnings side, it's been two years since Oracle missed estimates.
CTCAX TXN MDPEB OCLCF MDP ORCL

7
United Therapeutics In-Licenses Rights to IPF Candidate

2018-09-18 zacks - 1
United Therapeutics Corporation (UTHR - Free Report) announced that it has entered into an exclusive license agreement with privately held drug development company, Samumed LLC, for purchasing the North American rights to the latter’s IPF drug candidate, SM04646.
MNKD TXN BSTC PCRX MDPEB UTHR MDP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...